Clinical improvement in psoriasis with specific targeting of interleukin-23

  title={Clinical improvement in psoriasis with specific targeting of interleukin-23},
  author={Tamara Kopp and Elisabeth Riedl and Christine Bangert and Edward P. Bowman and Elli K Greisenegger and Ann Horowitz and Harald Kittler and Wendy M. Blumenschein and Terrill Mcclanahan and Thomas C. Marbury and Claus Otto Carl Zachariae and Danlin Xu and Xiaoli Shirley Hou and Anish Mehta and Anthe S. Zandvliet and Diana Montgomery and Frank van Aarle and Sauzanne Khalilieh},
Psoriasis is a chronic inflammatory skin disorder that affects approximately 2–3% of the population worldwide and has severe effects on patients’ physical and psychological well-being. The discovery that psoriasis is an immune-mediated disease has led to more targeted, effective therapies; recent advances have focused on the interleukin (IL)-12/23p40 subunit shared by IL-12 and IL-23. Evidence suggests that specific inhibition of IL-23 would result in improvement in psoriasis. Here we evaluate… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 43 times over the past 90 days. VIEW TWEETS
39 Citations
29 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 39 extracted citations


Publications referenced by this paper.
Showing 1-10 of 29 references

final results from 5 years of follow-up

  • Papp, K. A. et al. Long-term safety of ustekinumab in patie psoriasis
  • Br. J. Dermatol. 168, 844–854
  • 2013

what can we learn from new clinical data? J

  • Langley, R. G. Effective, sustainable biologic treatment of psoriasis
  • Eur. Acad. Dermatol. Venereol. 26 (suppl. 2), 21…
  • 2012

a randomized controlled trial

  • Bangert, C. et al. Clinical, cytological effects of pimecrolimus cream 1 after resolution o corticosteroids
  • Dermatology 222, 36–48
  • 2011

Similar Papers

Loading similar papers…